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Safety and anti-diabetic effects of Glucolevel, a mixture of dry extract of leaves of the Juglans
regia L, Olea europea L, Urtica dioica L and Atriplex halimus L were evaluated using in vivo
and in vitro test systems. No sign of toxic effects (using LDH assay) were seen in cultured
human fibroblasts treated with increasing concentrations of Glucolevel. Similar observations
were seen in vivo studies using rats (LD50: 25g/kg). Anti-diabetic effects were evidenced by the
augmentation of glucose uptake by yeast cells (2-folds higher) and by inhibition of glucose
intestinal absorption ( 49%) in a rat gut-segment. Furthermore, treatment with Glucolevel of
Streptozotocin-induced diabetic rats for 2–3 weeks showed a significant reduction in glucose
levels [above 400 50mg/dl to 210 22mg/dl (P50.001)] and significantly improved sugar
uptake during the glucose tolerance test, compared with positive control. In addition, glucose
levels were tested in sixteen human volunteers, with the recent onset of type 2 diabetes mellitus,
who received Glucolevel tablets 1 3 daily for a period of 4 weeks. Within the first week of
Glucolevel consumption, baseline glucose levels were significantly reduced from 290 40 to
210 20mg/dl. At baseline, a subgroup of eleven of these subjects had glucose levels below
300mg% and the other subgroup had levels 300mg%. Clinically acceptable glucose levels
were achieved during the 2–3 weeks of therapy in the former subgroup and during the 4th week
of therapy in the latter subgroup. No side effect was reported. In addition, a significant
reduction in hemoglobin A1C values (8.2 1.03 to 6.9 0.94) was found in six patients treated
with Glucolevel. Results demonstrate safety, tolerability and efficacy of herbal combinations of
four plants that seem to act differently but synergistically to regulate glucose-homeostasis.
Keywords: Arab herbal medicine–CAM–glucolevel–hyperglycemia–medicinal plants
Introduction
Diabetes is a predominant public health concern that has
increased steadily worldwide (1,2). The disease causes
substantial morbidity, mortality and long-term complica-
tions and remains an important risk factor for cardio-
vascular disease. With increasing rates of childhood and
adult obesity, diabetes is likely to become even more
prevalent over the coming decade. There are two types of
diabetes: type I and type II. Type I juvenile diabetes is an
auto-immune disease resulting in extensive destruction of
the beta cells in the pancreas (3), while the cause of type
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properly cited.II adult-onset diabetes remains poorly understood. All
patients with type I diabetes and part of type II diabetes
require daily insulin shots, replacement of the destroyed
beta cell mass via islets or transplant of pancreas in order
to survive (4).
Diabetes mellitus with retinopathic, neuropathic or
nephropathic complications is a common debilitating
and often life-threatening disease that constitutes a
significant risk factor in atherosclerosis. It is well
known that diabetes mellitus is associated with an
increased production of reactive oxygen species and
a reduction in antioxidative defences. The diabetic
induced oxidative stress is pathogenetically important
in diabetic complications (7). Antioxidant micro-
nutrients may thus significantly contribute to reduc-
tion or prevention of diabetic complications and
atherosclerosis (5–7).
The use of herbal remedies has been on the rise
worldwide (7,9–11). Glucolevel, a mixture of four herbs,
was developed according to the extensive herbal knowl-
edge of the Greek–Arab medical system. A system
developed over millennia, it consists of a sophisticated
and highly documented tradition, which is the basis
of modern European herbalism and medicine. Some of
the top selling herbal products of today such as garlic,
milk thistle and feverfew are derived from this system.
Since ancient times diabetes has been recognized and
its main symptoms were known by increased thirst,
frequent urination and tiredness experienced by the
diabetics.
Arab physicians and practitioners used series of plants
for treating these combined symptoms (named Zarab)
beside several instructions for consumption of specific
food and mild practices (12,13). The traditional Arabic–
Islamic medicine is still practiced and is greatly under
exploited, though it may provide effective new concepts
and a rich source of active herbal compounds. Two
extensive surveys recently carried out among practitioners
of Arabic medicine in the Middle East (8,9,14,16), have
disclosed 129 plant species that are still in common use.
Among them, 26 plant species are used for treating
people with diabetes mellitus. Juglans regia L, Atriplex
halimus L, Olea europea L and Urtica dioica L; they
were part of the strongly recommended medicinal plant
list (8,9). The safety of these four plants used in
the present study is evident by their use in folk
medicine through time. The tannins and phenolics
found in walnut leaves have been acknowledged
in treating high blood sugar both in Europe (10,11) and
in the Middle East (8,9).
Recent studies have emphasized the use of such extracts
as antioxidants in treating raised LDL levels both in
Scandinavia (17) and Japan (18). The safety of salt bush
is evident in Middle Eastern ethnobotany, reporting its
use for heart disease and hyperglycemia (8,9). It is also
widely used as animal food in Europe (19,20) and is of
high economic value in Sicily (21) suggesting that salt
bush is not toxic for mammals. Chromium and magne-
sium salts obtained using salt bush have been evidenced
to inhibit or prevent diabetes in sand rats
(22,23).The safety of olive leaves has been widely
documented both in Europe (23–27) and the Middle
East (8) as in the case of nettle in Europe (23,26–28),
in Asia (9,29) and in the United States where nettle
has a GRAS (Generally Recognised As Safe) status (23).
To consider anti-diabetic plants for clinical use, the
ideal plant should to possess the following properties:
Traditionally it has been used in more than one country,
has experimentally documented constituents, has hypo-
glycemic activity, low toxicity and botanical abundance
(23). We hypothesized that the extracts from the
four plants when combined may disclose synergistic
effects on different levels of glucose-insulin homeostasis
thus adding to therapeutic efficacy. This study was aimed
at investigating safety and efficacy of a fixed mixture
of these plants. As for safety, we performed in vitro and
animal studies. As for therapeutic efficacy, we carried out
controlled studies in animals and an open human
investigation.
Methods
Preparation of Glucolevel
The leaves of walnut, olive, nettle and salt bush were
collected, dried under shade, cleaned and sterilized by
steam for 2h and powdered to a fine grade as extracts.
Therefore, 10kg milled plants were extracted with 30g
food grade 50% ethyl alcohol for 2.5 hours at a 70
 
Ci na
stainless steel tank and filtered through a batch centri-
fuge. The residues were extracted with another 30kg,
50% ethyl alcohol and filtered through the batch
centrifuge. The filtrates from both extractions one and
two were mixed and evaporated. The yield of our
extraction was about 10%. Glucolevel tablets each of
510mg net weight were produced by adding 7mg
Vitamin C and 150mg tricalcium phosphate to 353mg
of dried plants. The yield of this extraction was also
about 10%. Glucolevel concentrations used in the
present study were determined according to traditional
uses, where total amount in capsules given for
each diabetic patient/day is equivalent to 7–10gm dried
plant leaves.
Analyses for Safety
Lactate Dehydrogenase
In the lactate dehydrogenase (LDH) assay, the leakage of
the cytoplasmic located enzyme LDH into the extra-
cellular medium was measured. Presence of the
422 Maintaining Blood-Glucose Levelexclusively cytosolic enzyme, LDH, in the cell culture
medium is indicative of cell membrane damage (45). For
the LDH assay, 1.5 10
4 cells from the fibroblasts cell
line 3T3 were seeded per well of 96-microtiter plates.
Twenty-four hours after cell seeding, cells were treated
with two concentrations of Glucolevel (180 and 360mg/
ml) varying. After 24, 48 and 72h of treatment, the
supernatants were collected from each well. Cell mono-
layers were then treated with a cell lysis solution for
30min at room temperature. LDH activity was measured
in both the supernatants and the cell lysate fractions by
using CytoTox 96, a non-radioactive cytotoxicity assay
kit (Promega, WI, USA), in accordance with the
manufacturer’s instruction. The intensity of the color is
proportional to LDH activity. The absorbance was
determined at 490nm with a 96-well plate ELISA
reader. The percent of LDH release from the cells was
determined using the formula: LDH relea-
se¼(absorbance of the supernatant)/(absorbance of the
supernatant and cell lysate)
*100.
LD50
32 Male Spague–Dawley rats (average weight:161 17g)
were divided into four groups. Increasing large single
doses of Glucolevel (up to 50g/Kg) were placed directly
into the stomach of each group and were observed for
14 days to determine the LD50.
In-vitro Efficacy
Glucose uptake by yeast cells
Glucose transport through yeast cell membrane is based
upon the Warburg method of (1946), which is a
fermentation process. The amount of CO2 produced
was measured in mililiters during anaerobic control
conditions and during the addition of Glucolevel extract,
(2mg/ml) and taken to reflect the extent of glucose-
entrance into yeast cells (30).
Glucose Intestinal Absorption (inverted intestine sac test)
The upper part of the small intestine was obtained from
Sprague Dawley male rats (average weight: 161 17g),
washed with physiologic solution and incubated in Krebs
solution. The inner surface of the gut segment was
inverted with the help of the Pasteur Pipette. Then the
bottom part of the inverted segment was tied before
filling it with Krebs solution and placed in Erlenmeyer
containing 7ml of 1% starch solution and 1ml of 1%
pancreatin solution. The apparatus was bubbled with gas
composed of 95% O2 and 5% CO2. The glucose amount
obtained outside the inverted intestine was taken to
represent starch digestion, whereas the glucose amount
inside the sac was taken to represent glucose absorption
in the gut. Determination of glucose values was done
using the DNS method (31,32). To avoid variations
between inverted intestine segment weights, protein
concentrations were determined at the final stage with
the Lowry method (33) and segment weights were
adjusted. Tests were performed at baseline and during
the addition of various Glucolevel concentrations.
Efficacy in Rats
Diabetes mellitus was induced in 14 rats by a single
intraperitoneal injection of 80mg Streptozotocin/kg in
sterile 0.1M citrate buffer (pH 4.5). Diabetes mellitus was
developed gradually in them, as assessed by blood
glucose levels, which reached about 400mg within one
week. These rats were treated with 150mg Glucolevel
extract/kg/day for 3 weeks. An oral glucose tolerance test
was performed on three groups of rats with a glucose
load of 3g/kg. Diabetic rats were divided into two groups
of seven rats each during glucose tolerance testing and
one group only received Glucolevel 150mg/kg together
with the glucose load. The same glucose load was given
to 6 non-diabetic rats the third group.
Clinical Investigations: Selection of Volunteers
Human volunteers were selected on the basis of type II
diabetes mellitus of recent onset, i.e. they were only on
diet therapy and not on treatment with hypoglycemic
pharmacologic agents. They were recruited from four
General-Physician-Clinics in the Galilee region (Israel)
and were motivated to take herbal therapy. After a
thorough review of Glucolevel-components, they were
asked to continue their daily activities; leave diet
habits unchanged and take one tablet of Glucolevel
3 times daily. They were also asked to restrain from
consuming any medications during the study period of
4 weeks. An informed consent was obtained from each
subject who was given a box containing 90 tablets
of Glucolevel.
Clinical Protocol
At baseline, glucose blood levels were estimated in
each subject who was scheduled for the next visit in
1 week and was asked to return the Glucolevel box so
that returned tablets could be counted as the only
measure of patient compliance with the protocol. This
was repeated during each of the three consequent visits
when glucose levels were estimated and careful investiga-
tions of well-being as well as any adverse effects were
undertaken.
Statistics
The Wilcoxon signed rank was used. Comparison
between groups was performed by the Wilcoxon
eCAM 2008;5(4) 423rank-sum test. A 0.05 level of significance was set.
Data obtained were expressed as mean standard error
of mean (SEM).
Results
Safety
The safety of Glucolevel was evaluated both in vitro
using LDH assay on cultured fibroblasts and in vivo
by measuring the LD50 in rats. Fig. 1 shows
LDH-release from 3T3 cells treated for 24h (Fig. 1A),
48h (Fig. 1B), and 72h (Fig. 1C) with 180 or 360mg
Glucolevel/ml. Compared to untreated control cells, no
significant change in LDH-release was observed whether
as a function of increasing the concentrations or as a
function of an increased incubation period. Similar
observations were observed in vivo by measuring the
LD50 in rats. Glucolevel showed an LD50 by concentra-
tion of about 25g/kg.
Efficacy
Glucose Uptake
Fig. 2 shows the amount of CO2 produced within 1h of
fermentation in yeast cells under controlled conditions
with the presence/absence of 2mg/ml of Glucolevel. In
this assay, CO2 is a marker for glucose inside yeast cells,
the more CO2 is produced the more glucose enters into
the yeast cells. As seen in Fig. 2, glucolevel significantly
increased the glucose uptake through the yeast plasma
membrane. The glucose level was two-fold higher after
Glucolevel treatment, compared with the control group.
Glucose Transport through Inverted Intestine
Table 1 shows results of glucose measurements inside and
outside the inverted intestine at baseline and during the
addition of 10, 20 and 30mg glucolevel/ml. Glucolevel at
concentrations of 20 and 30mg/ml significantly decreased
the glucose values inside the inverted intestine (P50.01),
whereas, slight but insignificant reductions of these values
were obtained outside the inverted intestine.
Glucolevel Reducing Glucose Levels in
Streptozotocin-induced Diabetic Rats
Induction of diabetes mellitus by Streptozotocin was confi-
rmed by measuring the glucose levels. Within 1 week,
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Figure 1. LDH-release in arbitrary units from cultured human
fibroblasts. Cells were treated with two concentrations of Glucolevel
(180 and 360mg/ml) for 24h (A),4 8 h(B) and 72h (C). Data shown
represents the meanþSEM from three independent experiments carried
out in triplicates.
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Figure 2. The amount (ml) of CO2 produced within 1h of fermentation
of yeast cells under control conditions (lower curve) and during the
addition of 2mg Glucolevel/ml (upper curve).
Table 1. Glucose values measured inside and outside the inverted
intestine sac placed in starch-pancreatin solution at control conditions
(0) and during the addition of different concentrations of the Glucolevel
extract
Glucolevel (mg/ml) Glucose values
mg/ml protein
inside the sac
Glucose values
mg/ml protein
outside the sac
0 2.9 0.2 28 2
10 2.7 0.3 27 3
20 1.6 0.3
* 25 5
30 1.5 0.1
* 24 4
*P50.01 versus control conditions (0).
424 Maintaining Blood-Glucose Levelglucose levels reached a level of 400 50mg/dl in the
14 rats. Treatment with Glucolevel for three weeks
significantly reduced glucose levels in these rats to
210 22mg/dl (P50.001). Fig. 3 summarizes glucose
tolerance testing in these rats with and without the
addition of Glucolevel 150mg/kg and compares the
results with those obtained in six non-diabetic rats
during the same testing. Non-diabetic rats exhibit a
normal glucose tolerance curve (lower curve). Diabetic
rats with Glucolevel added to the glucose load, and they
disclose a near normal curve (middle curve) with the 2–
3h glucose levels of 180 10mg%, which is significantly
(P50.01) lower than the levels (290 30mg/dl) disclosed
in diabetic rats without additional Glucolevel (upper
curve). These levels in the latter group are still above
baseline levels.
Clinical Analyses
The 16 test persons recruited for the study had an age
range of 48–67 years and their compliance with the study
protocol was excellent. No test person took any
pharmacologic drug during the study period. No minor
or major adverse effect was noted and the Glucolevel was
well tolerated by all subjects. During the first week of
Glucolevel consumption, baseline glucose levels were
reduced from 290 40mg/dl to 210 20mg/dl in these
subjects (P50.001). According to baseline glucose levels,
a subgroup of 11 had glucose levels below 300mg/dl and
the other subgroup had levels 300mg%. As shown in
Fig. 4, the former subgroup achieved clinically acceptable
glucose levels during the 2–3 week of Glucolevel
consumption while the latter group needed 1 week
more to achieve clinically acceptable glucose levels.
Table 2 shows the effects of glucolevel on the glucose
level and hemoglobin A1C (HbA1C) in six diabetic
patients, who did not fully respond to conventional
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Figure 3. Glucose tolerance testing in normal rats (lower curve) and in
two groups of diabetic rats treated with Glucolevel for 3 weeks
(upper two curves). The middle curve was obtained from one diabetic
group to which the same extract was added to the glucose load during
testing.
Table 2. The effects of Glucolevel on blood glucose levels and HbA1C values with and without conventional anti-diabetes drugs
# Diabetes
duration
(Years)
Diabetes Drugs Glucose values
without Glucolevel
Glucose values
with Glucolevel
HbA1C-A With
Diabetes Drugs
HbA1C-B With
Diabetes drugs
HbA1-C with
Diabetes drugs
and Glucolevel
1 7 GlucophageþGlubin 180–250 90–130 7.8 8 6.3
2 9 GlucophageþGlubinþAvandia 200–290 110–140 7.5 7.9 6.5
3 11 Insulin 45 units 200–270 120–150 9.5 8.7 7.3
4 5 Glucophage 130–150 80–120 7.9 7.7 6.7
5 6 Insulin 100 units 180–200 90–140 10 10 8.7
6 4 GlucophageþGlubin 250–200 100–120 7.9 7 6.2
Average 8.4 1.04 8.2 1.03 6.9 0.94
The tests were conducted in 22 diabetic patients who didn’t fully respond to conventional therapeutics and remained with high glucose levels. The
patients were allowed to continue taking their medication were the sugar levels being continually monitored and HbA1C value was determined after
three months according to Saudek et al. (46).
HbA1C-A: Values of A1C of the patients were determined during treatments by their doctors (using only conventional drugs).
HbA1C-B: Values of A1C of the patients were determined during treatments by their doctors (using only conventional drugs) in order to make
medical comparison to the treatment efficacy (drugs have to reduce A1C values).
HbA1C-C: Values of A1C after taking diabetes drugs and Glucolevel capsules.
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Figure 4. Glucose levels during a 4 week period of Glucolevel
consumption 1 tablet 3 daily in those subjects with baseline glucose
levels below 300mg/dl (lower curve) and in those with baseline glucose
levels 300mg/dl (upper curve).
eCAM 2008;5(4) 425therapeutics and remained with high glucose levels.
The test aimed to clarify whether Glucolevel supplemen-
tation can contribute to reduced the glucose levels in this
group. The patients were allowed to continue taking their
medication during the whole test period. The sugar levels
were continually monitored and HbA1C values were
determined after three months. The results indicated a
significant reduction in HbA1C values compared with
conventional treatment and showed positive synergetic
effect.
Discussion
Despite all the marvelous advancements in modern
medicine, traditional herbal medicine has always been
practiced. Cultural beliefs and practices often lead to self-
care or home remedies in rural areas and consultation
with traditional healers. Alternative therapies have been
utilized by people in our region who have faith in
spiritual healers. About 400–450 medicinal plants are
found in the Palestinian-Israelian region and about
129 plant species are still used for treating of various
human diseases, including diabetes, liver diabetes, as well
as skin, respiratory, digestive and cancer diabetes,
along with other diseases (14–16). It has already been
mentioned that since ancient times diabetes has been
recognized and its main symptoms were known by
increased thirst, frequent urination and tiredness experi-
enced by diabetics. Arab physicians and practitioners
had used series of plants for treating these combined
symptoms. Juglans regia L, Atriplex halimus L, Olea
Europea L and Urtica dioica L were part of the strongly
recommended anti-diabetic medicinal plant. Therefore, a
mixture of extracts of these four plants was prepared and
its efficacy and safety were evaluated in the present study.
Safety Studies of Glucolevel
Our data indicates a high level of safety in Glucolevel
with very large concentrations of 25g/kg to yield the
LD50. Glucolevel at concentrations as high as 360mg/ml
did not show any sign of cellular toxicity as evidenced by
LDH-release. Similar results were reported for plants
used for the preparation of Glucolevel. For example,
(i) in a long-term clinical study of nettle extract for
benign prostatic hyperplasia (37), a daily dose of 320mg
was well tolerated and showed no evidence of adverse
effects. (ii) Extracts of walnut leaves protect against
cellular-toxicity and to reduce cyclophosphamide-induced
biochemical toxicity (38). (iii) Several extracts of salt bush
have been reported to be non-toxic to the stored plant
insect (39). (iv) As for olive leaves, doses as high as
1200mg/kg for 60 days in rats were completely atoxic
(40), and aqueous extracts from these leaves were given
to two groups of hypertensive patients with no side
effects and with a promising clinical efficacy (41).
As experienced in good clinical practice, smaller doses
of synergistic drugs may yield a better therapeutic
efficacy with lower side effects. This could explain the
fact that Glucolevel was well tolerated by all our subjects
and no adverse effects could be traced.
Efficacy studies with Glucolevel
Anti-diabetic effects of Glucolevel were seen in (i) glucose
uptake by yeast cells, (ii) inhibition of glucose intestinal-
absorption in a rat gut-segment, (iii) in Streptozotocin-
induced diabetic rats for 2–3 weeks and (iv) in clinical
studies with sixteen human volunteers with recent onset
of type 2 diabetes mellitus who received Glucolevel
tablets 1 3 daily for a period of 4 weeks. The used
Glucolevel concentrations in the present study were
determined according to traditional uses, where the
total amount in capsules given for each diabetic
patient/day is equivalent to 7–10gm dried plant leaves.
The main pathologic effects in diabetes mellitus consist
of excessive hepatic glucose production, peripheral insulin
resistance and defective b-cell secretory function.
Available per patient, oral hypoglycemic agents are
directed at stimulating insulin secretion (sulfonylureas),
inhibiting excessive hepatic glucose production (met-
formin or biguanides), delaying the absorption of
carbohydrates in the gut by inhibiting a-glucosidase
(acarbose) or reducing insulin resistance (troglitazone)
primarily in skeletal muscle, but also in adipose tissue
(34). We propose that the combination of the four herbs
in Glucolevel may represent a combination of the four
different action sites of oral hypoglycemic drugs (34).
Furthermore, chromium-magnesium salts contained in
salt bush (23) and evidenced as an insulin cofactor to
facilitate glucose entry into muscle and fat cells (35,36),
as well as the antioxidants contained in walnut and olive
leaves (17,25), may all add to the therapeutic efficacy of
Glucolevel.
The efficacy of Glucolevel in diabetic animals was evident
during the treatment given for 3 weeks as it reduced
glucose levels from about 400 to about 200mg/dl. As
shown in Fig. 3, these diabetic animals still disclosed an
abnormal glucose tolerance curve. The addition of
Glucolevel to the glucose load almost normalized the
glucose tolerance curve in these animals by reducing both
the hyperglycemic peak and the late glucose levels. A
treatment period of 2–3 weeks achieved adequate glycemic
control in subjects with baseline glucose levels below
300mg/dl. Adequate glycemic control in those with
higher baseline glucose levels was achieved after an
additional treatment period of 1–2 weeks more.
Possible Action Mechanism of Glucolevel
Scientific evidence obtained so far is indicating hypogly-
cemic and antioxidant properties of each of the four
426 Maintaining Blood-Glucose Levelherbs contained in Glucolevel. The main active ingredient
in the olive leaf was reported to be oleuropeoside, which
disclosed a distinct hypoglycemic effect at a dose of
16mg/kg (42), together with hypotensive and hypolipi-
demic properties (40,42). Tannins and polyphenolics in
walnut leaves were discovered to be potent antioxidants
(17) and revealed strong scavenging activity against
both superoxide and hydroxyl radicals (43). An animal-
model for diabetogenesis and obesity (22) proved that
salt bush is an extremely effective antidiabetic herb
(22, 23) and that also shows an insulin potentiating effect
(35,36). There is also the evidence that nettle extracts
possess hypoglycemic properties and improve glucose
tolerance (23,45). The in vitro experiments disclosing
that Glucolevel facilitates glucose entry into yeast cells
during anerobic fermentation may be attributed to
an effect of salt bush content in the product. The
nettle component is supposed to decrease glucose
production by the liver whereas; oleuropein and tannins
in olive and walnut leaves are supposed to act as
a-glucosidase inhibitors thus reducing the absorp-
tion of carbohydrates in the gut. Such an effect was
evidenced in our experiments with the inverted
intestine segment at a concentration of 20mg/ml of the
Glucolevel extract (Fig. 5).
Conclusions
We selected four medicinal plants used in the traditional
Arab herbal medicine for the preparation of Glucolevel.
Our results obtained in the present study demonstrate
safety, tolerability and efficacy of such herbal combina-
tions of the four plants that seem to act differently but
synergistically to regulate glucose-homeostasis.
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